Knight Therapeutics Inc. and Helsinn Healthcare SA announced that Knight, through one of its wholly-owned subsidiaries, and Helsinn have entered into an exclusive license, distribution and supply agreement for AKYNZEO ® oralIV (netupitantpalonosetron fosnetupitantpalonosetron) in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI ® oralIV (palonosetron) in Canada (the "Products"). According to IQVIA, sales of AKYNZEO ® in Canada and Brazil were approximately $7 million in 2021. Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories.

Knight will begin commercial activities following a transition period from Helsinn's current licensees.